U.S.-based pharmaceutical giant Pfizer together with a German company, founded by a Turkish national, will be working on the co-development and distribution of a potential mRNA-based coronavirus vaccine aimed at preventing COVID-19 infection.

The collaboration aims to accelerate development of BioNTech’s potential first-in-class COVID-19 mRNA vaccine program, BNT162, which is expected to enter clinical testing by the end of April 2020, said a statement issued by BioNTech on Tuesday.

“We are proud that our ongoing, successful relationship with BioNTech gives our companies the resiliency to mobilize our collective resources with extraordinary speed in the face of this worldwide challenge,”

Read more: Pfizer, BioNTech jointly work on coronavirus vaccine